C

Celea Therapeutics

Clinical-stage biopharma developing deupirfenidone for IPF

Head of Corporate Communications

PR & CommunicationsConfirmed live in the last 24 hours
Full-timeBoston, MA, USA

About the Job

Requirements

  • A bachelor's degree in communications, business, finance, life sciences, journalism, or a related field is required; equivalent experience is considered.
  • At least 8 years of experience in investor relations, corporate communications, financial communications, biotechnology or pharmaceutical communications, healthcare capital markets, or a closely related field.
  • Experience preparing corporate decks, message maps, press releases, and conference messaging.
  • Excellent writing and editing skills, including drafting polished, executive-ready materials and translating complex science into concise business language.
  • Strong project management skills and the ability to operate independently in a fast-paced, early-stage environment with limited infrastructure and shifting priorities.
  • Proficiency using artificial intelligence tools to improve quality, accelerate drafting and research, and build repeatable workflows while maintaining human judgment and accountability.
  • Familiarity with rare disease, pulmonary, respiratory, or specialty pharmaceutical markets.

Responsibilities

  • Own the integrated communications workplan, ensuring external messaging is clear, consistent, scientifically credible, regulatorily appropriate, and aligned with company strategy.
  • Develop, write, and maintain corporate external-facing materials, including the corporate deck, external presentations, conference materials, press releases, executive talking points, Q&A documents, website updates, and social media content.
  • Partner with executive leadership, Finance, Legal, Clinical, Medical Affairs, and external advisors to support corporate objectives, including conference planning with Medical Affairs, Q&A preparation, and company communications processes.
  • Partner with Leadership and HR on internal communications, providing strategic messaging and communications support for employee announcements, program rollouts, company news, and other key organizational updates.
  • Translate complex clinical, scientific, regulatory, and commercial information into balanced, accurate, audience-appropriate messaging for healthcare stakeholders, media, prospective employees, patients, and caregivers.
  • Lead proactive and reactive communications around corporate, clinical, financing, conference, and business milestones, balancing planned news flow with opportunistic visibility opportunities between major events.
  • Coordinate media relations and thought leadership activities, including media lists, inbound inquiries, executive preparation, earned media opportunities, and compliant amplification of scientific congress activity and scientific data.
  • Oversee external communications, design, wire distribution, website, conference, and agency partners, including scopes of work, timelines, budgets, deliverable quality, and issue escalation.
  • Lead strategic planning for the web presence across key audiences, including patients and caregivers, healthcare providers, career seekers, investors, media, and other external stakeholders.
  • Create practical processes, templates, message maps, trackers, and version-control standards that enable a lean company to operate with public-company-like discipline.
  • Prepare the infrastructure for a future Communications team, including scalable processes, tools, workflows, agency interfaces, and role definitions that can support team growth.

About the Company

Celea Therapeutics

Clinical-stage biopharma developing deupirfenidone for IPF

Celea Therapeutics develops and advances treatments for severe respiratory diseases, focusing on late-stage development of deupirfenidone (LYT-100), a deuterated form of pirfenidone. Its lead program targets idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and is prepared for Phase 3 trials. Deupirfenidone aims to slow lung function decline and improve tolerability by changing how the drug is processed in the body, potentially offering advantages over current IPF therapies. The company pursues a Phase 3 head-to-head trial (SURPASS-IPF) against an approved therapy, supported by Orphan Drug Designations and funding from investors, with PureTech Health retaining a meaningful stake.

Company size
11-50
Company stage
Growth Equity (Non-Venture Capital)
Total funding
$180M
Headquarters
Boston, MA
Founded
Not listed

Recently Posted Jobs

Explore more opportunities at Celea Therapeutics

See more jobs